Factors affecting platinum sensitivity in cervical cancer
- Authors:
- Rina Kato
- Kiyoshi Hasegawa
- Yutaka Torii
- Yasuhiro Udagawa
- Ichio Fukasawa
-
Affiliations: Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo 160‑0023, Japan, Department of Obstetrics and Gynecology, Dokkyo Medical University, Mibu, Tochigi 321‑0293, Japan, Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, Toyoake, Aichi 470‑1192, Japan - Published online on: September 25, 2015 https://doi.org/10.3892/ol.2015.3755
- Pages: 3591-3598
This article is mentioned in:
Abstract
 |
|
World Health Organization; International Agency for Research on Cancer: Cervical Cancer - Estimated Incidence. Mortality and Prevalence Worldwide in. 2012.http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=cervix | |
|
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cervical Cancer. Version 1. 2013.http://www.alabmed.com/uploadfile/2014/0221/20140221105002791.pdfAccessed. September 11–2015 | |
|
National Cancer Institute: Cervical cancer treatment. http://www.cancer.gov/types/cervical/patient/cervical-treatment-pdqAccessed. September 11–2015 | |
|
Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J and Cella D: Phase III trial of four cisplatin-containing doublet combination in stage IVB, recurrent or persistent cervical carcinoma: A gynecologic oncology group study. J Clin Oncol. 27:4649–4655. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Thigpen JT: The role of chemotherapy in the management of carcinoma of the cervix. Cancer J. 9:425–432. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tattersall MH, Ramirez C and Coppleson M: A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastasis. Gynecol Oncol. 46:176–181. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Takeshima N, Umayahara K, Fujiwara K, Hirai Y, Takizawa K and Hasumi K: Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate-and high-risk stage IB-IIA cervical cancer. Gynecol Oncol. 103:618–622. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lahousen M, Haas J, Pickel H, Hackl A, Kurz C, Ogris H, Stummvoll W and Winter R: Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial. Gynecol Oncol. 73:196–201. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Kato R, Hasegawa K, Achiwa Y, Okamoto H, Torii Y, Oe S and Udagawa Y: Predicting nedaplatin sensitivity of cervical cancer using the histoculture drug response assay. Eur J Gynaecol Oncol. 32:381–386. 2011.PubMed/NCBI | |
|
Yamamoto K, Kokawa K, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H and Takizawa K: Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study. Oncol Rep. 21:1005–1009. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe Y, Nakai H, Etoh T, Kanemura K, Tsuji I, Ishizu A and Hoshiai H: Feasibility study of docetaxel and nedaplatin for recurrent squamous cell carcinoma of the uterine cervix. Anticancer Res. 28:2385–2388. 2008.PubMed/NCBI | |
|
Detre S, Jotti Saclani G and Dowsett M: A ‘quickscore’ method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 48:876–878. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, et al: ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 44:54–60. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Vescio RA, Connors KM, Kubota T and Hoffman RM: Correlation of histology and drug response of human tumors grown in negative-state three-dimensional histoculture and in nude mice. Proc Natl Acad Sci USA. 88:5163–5166. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Hoffman RM: In vitro assay for chemotherapy sensitivity. Crit Rev Oncol Hematol. 15:99–111. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa AR and Hoffman RM: Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res. 20:2049–2054. 2000.PubMed/NCBI | |
|
Yoshimasu T, Ohta F, Oura S, Tamaki T, Shimizu Y, Naito K, Kiyoi M, Hirai Y, Kawago M and Okamura Y: Histoculture drug response assay for gefitinib in non-small-cell lung cancer. Gen Thorac Cardiovasc Surg. 57:138–143. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fujita Y, Hiramatsu M, Kawai M, Nishimura H, Miyamoto A and Tanigawa N: Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer. Oncol Rep. 21:499–505. 2009.PubMed/NCBI | |
|
Furukawa T, Kubota T and Hoffman RM: Clinical application of the histoculture drug response assay. Clin Cancer Res. 1:305–311. 1995.PubMed/NCBI | |
|
Furukawa T, Kubota T, Tanino H, et al: Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res. 20:3657–3658. 2000.PubMed/NCBI | |
|
Tanino H, Oura S, Hoffman RM, et al: Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res. 21:4083–4086. 2001.PubMed/NCBI | |
|
Hirano Y, Kageyama S, Ushiyama T, Suzuki K and Fujita K: Clinical usefulness of chemotherapy based on an in vitro chemosensitivity test in urothelial cancer patients. Anticancer Res. 21:4061–4066. 2001.PubMed/NCBI | |
|
Singh B, Li R, Xu LI, et al: Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck. 24:437–442. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Morioka H, Yabe H, Morii T, Yamada R, Kato S, Yuasa S and Yano T: In vitro chemosensitivity of human soft tissue sarcoma. Anticancer Res. 21:4147–4151. 2001.PubMed/NCBI | |
|
Nakata S, Aoki D, Ohie S, Horiguchi M, Suzuki N, Kanasugi M, Susumu N, Udagawa Y and Nozawa S: Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: Sensitivity to cisplatin and clinical response. Int J Gynecol Cancer. 15:445–452. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kanasugi M, Aoki D, Suzuki N, Susumu N, Nakata S, Horiguchi M, Udagawa Y and Nozawa S: Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer. Int J Gyenecol Cancer. 16:409–415. 2006. View Article : Google Scholar | |
|
Bonetti A, Zaninelli M, Rodella S, Molino A, Sperotto L, Piubello Q, Bonetti F, Nortilli R, Turazza M and Cetto GL: Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Res Treat. 38:289–297. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
O'Reilly SM, Camplejohn RS, Rubens RD and Richards MA: DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer. 28:681–683. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Sultana H, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Sato S, Kamazawa S, Ohwada M, Suzuki M and Terakawa N: Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol. 14:214–219. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Costa S, Terzano P, Santini D, Ceccarelli C, Martoni A, Angelelli B, Panetta A, Bovicelli A, Cristiani P, Lipponen P, et al: Neoadjuvant chemotherapy in cervical carcinoma: Regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol. 116:729–737. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, et al: A comparative study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56:689–693. 1996.PubMed/NCBI | |
|
Sato S, Kigawa J, Minagawa Y, Okada M, Shimada M, Takahashi M, Kamazawa S and Terakawa N: Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer. 86:1307–1313. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Lu X and Feki A: Phenotypic features with p53 alterations related to human papillomavirus and prognostic evaluation in cervical cancer. Int J Gynecol Cancer. 16:708–717. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Soussi T, Dehouche K and Béroud C: P53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat. 15:105–113. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Kraiss S, Spiess S, Reihsaus E and Montenarh M: Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformation. Exp Cell Res. 192:157–164. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1674–1677. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Hirao A, Kong YY, Matsuoka S, et al: DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287:1824–1827. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1–6. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Pillai MR, Jayaprakash PG and Nair MK: Bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma. J Cancer Res Clin Oncol. 125:55–60. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Rajkumar T, Rajan S, Baruah RK, Majhi U, Selvaluxmi G and Vasanthan A: Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol. 19:556–560. 1998.PubMed/NCBI | |
|
Wootipoom V, Lekhyananda N, Phungrassami T, Boonyaphiphat P and Thongsuksai P: Prognostic significance of Bax, Bcl-2 and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol Oncol. 94:636–642. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Pezzella F, Turley H, Kuzu I, et al: Bcl-2 protein in non-small cell lung carcinoma. N Engl J Med. 329:690–694. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Joensuu H, Pylkkänen L and Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol. 145:1191–1198. 1994.PubMed/NCBI | |
|
Diebold J, Baretton G, Felchner M, et al: Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinoma. Am J Clin Pathol. 105:341–349. 1996.PubMed/NCBI | |
|
Crawford RA, Caldwell C, Iles RK, et al: Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br J Cancer. 78:210–214. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Itoi T, Yamana K, Bilim V, Takahashi K and Tomita F: Impact of frequent bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer. 90:200–205. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Saito T, Takehara M, Tanaka R, Lee R, Horie M, Wataba K, Ito E and Kudo R: Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. Gynecol Oncol. 92:284–292. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Munakata S, Watanabe O, Ohashi K and Morino H: Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance. Am J Clin Pathol. 123:879–885. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Padovan P, Salmaso R, Marchetti M and Padovan R: Prognostic value of bcl-2, p53 and Ki-67 in invasive squamous carcinoma of the uterine cervix. Eur J Gynecol Oncol. 21:267–272. 2000. | |
|
Mukherjee G, Freeman A, Moore R, Kumaraswamy, Devi KU, Morris LS, Coleman N, Dilworth S, Prabhakaran PS and Stanley MA: Biologic factors and response to radiotherapy in carcinoma of the cervix. Int J Gynecol Cancer. 11:187–193. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Gown AM and Willingham MC: Improved detection of apoptotic cells in archival paraffin sections: Immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem. 50:449–454. 2000. View Article : Google Scholar | |
|
Levine EL, Renehan A, Gossiel R, Davidson SE, Roberts SA, Chadwick C, Wilks DP, Potten CS, Hendry JH, Hunter RD, et al: Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol. 37:1–9. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Levine EL, Davidson SE, Roberts SA, Chadwick CA, Potten CS and West CM: Apoptosis as predictor of response to radiotherapy in cervical carcinoma. Lancet. 344:4721994. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JY, Cho HY, Lee KC, Hwang YJ, Lee MH, Roberts SA and Kim CH: Tumor apoptosis in cervical cancer: Its role as a prognostic factor in 42 radiotherapy patients. Int J Cancer. 96:305–312. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Tomozawa S, Tsuno NH, Sunamio E, Hatano K, Kitayama J, Osada T, Saito S, Tsuruo T, Shibata Y and Nagawa H: Cyclooxygenase-2 overexpression correlates with tumor recurrence, especially haematogenous metastasis of colorectal cancer. Br J Cancer. 83:324–328. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GW and Lalani EN: Cytoplasmic induction and overexpression of cyclooxygenase-2 in human prostate cancer: Implication for prevention and treatment. BJU Int. 86:736–741. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hwang D, Skollard D, Byerne J and Levine E: Expression of Cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 90:455–460. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T and Takahashi T: Prognostic significance of elevated cyclooxygenase-2 expression in primary resected lung adenocarcinomas. Clin Cancer Res. 5:1001–1005. 1999.PubMed/NCBI | |
|
Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The relationship between Cyclooxygenase-2 expression and colorectal cancer. JAMA. 282:1254–1257. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Liu XH, Yao S, Kirschenbaum A and Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down regulation bcl-2 expression in LNCaP cells. Cancer Res. 58:4254–4249. 1998. | |
|
Ferrandina G, Lauriola L, Distefana MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G and Ranelletti FO: Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol. 20:973–981. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
de Laat WL, Appeldoorn E, Jaspers NG and Hoeijmakers JH: DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem. 273:7835–7842. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI | |
|
Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A and Aizawa H: Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 98:1336–1343. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 16:309–316. 1998.PubMed/NCBI | |
|
Kim MK, Cho KJ, Kwan GY, et al: ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 44:54–60. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, et al: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 18:522–528. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Steffensen KD, Waldstrøm M and Jakobsen A: The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer. 19:820–825. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Scheil-Bertram S, Tylus-Schaaf P, du Bois A, Harter P, Oppitz M, Ewald-Riegler N and Fisseler-Eckhoff A: Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. Gynecol Oncol. 119:325–331. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Park JS, Jeon EK, Chun SH, Won HS, Lee A, Hur SY, Lee KH, Bae SN, Yoon SC and Hong SH: ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO 2B uterine cervix cancer. Gynecol Oncol. 120:275–279. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hasegawa K, Kato R, Torii Y, Ichikawa R, Oe S and Udagawa Y: The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma. Int J Gynecol Cancer. 21:1479–1485. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Costa S, Terzano P, Bovicelli A, Martoni A, Angelelli B, Santini D, Ceccarelli C, Lipponen P, Erzén M, Syrjänen S and Syrjänen K: CD44 isoform 6 (CD44v6) is a prognostic indicatior of the response to neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol. 80:67–73. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Chung HH, Kim MK, Kim JW, Park NH, Song YS, Kang SB and Lee HP: XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol. 103:1031–1037. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Faried LS, Faried A, Kanuma T, Sano T, Nakazato T, Tamura T, Kuwano H and Minegishi T: Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol Rep. 16:57–63. 2006.PubMed/NCBI |
